Feb 5 (Reuters) - GSK GSK.L forecast sales in 2025 to grow between 3% and 5%, and reported a better-than-expected fourth quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines division.
The company reported core earnings per share of 23.2 pence on sales of 8.12 billion pounds ($10.13 billion) for the quarter ended Dec. 31, compared with 19 pence on sales of 7.75 billion pounds expected by analysts in an LSEG poll.
($1 = 0.8017 pounds)